Clinical Trials
6 trialsNCT05396859 2026-04-27
Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia
OHSU Knight Cancer Institute
Phase 1 Active not recruiting
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT03056599 2021-09-24
Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma
Presage Biosciences
Phase 1 Completed
NCT02097810 2021-06-09
STARTRK-1
Hoffmann-La Roche
Phase 1 Completed
NCT03961100 2020-09-07
A Performance and Bioavailability Study of Entrectinib in Healthy Volunteers.
Genentech, Inc.
Phase 1 Completed
NCT03330990 2018-08-21
Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients
Hoffmann-La Roche
Phase 1 Completed